Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Alicia Gerke
Modality
Small molecule
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00981747CT.gov Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis | — | Terminated | — | — | — |
NCT00467831CT.gov Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pulmonary Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Losartan (this asset) | Alicia Gerke | P2/3 | B · 62 |
| Acetylcysteine | Boehringer Ingelheim | P3 | BB |
| Nintedanib | Boehringer Ingelheim | P3 | BB |
| Admilparant | Bristol-Myers Squibb | P3 | BB |
| Pirfenidone | Boehringer Ingelheim | P2 | BB |
| Sildenafil | Alicia Gerke | P3 | BB |
| Interferon Gamma-1B | NYU Langone Health | P3 | BB |
| Tamoxifen | Tata Memorial Hospital | P3 | B |
| [68ga]cbp8 | Peter Caravan | P2 | B |
+26 more in the Pulmonary Fibrosis cohort
Other indications for Losartan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypertensive Disorder | — | P4 | BBB · 76 |
| Cardiovascular Disorder | — | P4 | BB · 66 |
| Psychotic Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Losartan in Pulmonary Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/losartan-pulmonary-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →